Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trialProactive Investors • 03/26/25
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) TreatmentGlobeNewsWire • 03/26/25
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' NowZacks Investment Research • 03/25/25
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409Proactive Investors • 03/20/25
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409GlobeNewsWire • 03/20/25
Candel Therapeutics appoints cancer immunology expert to research advisory boardProactive Investors • 03/18/25
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.GlobeNewsWire • 03/18/25
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/13/25
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMIProactive Investors • 02/28/25
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic DataSeeking Alpha • 02/25/25
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapyProactive Investors • 02/25/25
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerGlobeNewsWire • 02/25/25
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submissionProactive Investors • 01/13/25
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025GlobeNewsWire • 01/13/25
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseasesProactive Investors • 12/23/24
Candel Therapeutics rides high on promising Phase 3 data, funding boostProactive Investors • 12/19/24
Candel Therapeutics raises $92M in public offering following prostate cancer trial successProactive Investors • 12/16/24
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/16/24
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga • 12/13/24
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary GoalZacks Investment Research • 12/12/24